Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QX001S versus ustekinumab in adults with moderate to severe plaque psoriasis
ChiCTR2100045970Phase 3Recruiting
- Sponsor
- Peking University People's Hospital
- Start
- Apr 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in plaque psoriasis comparing QX001S injection treatment group with Ustekinumab injection treatment group (2 arms). Primary endpoint: Proportion of subjects achieving PASI75. Started Apr 2021; status: recruiting.
02
Drugs
ustekinumab biosimilar QX001Sustekinumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on ChiCTR2100045970.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100045970.